ANAB vs. ALBO, RNA, TGTX, INDV, JANX, ACAD, ARVN, BHC, MRVI, and DCPH
Should you be buying AnaptysBio stock or one of its competitors? The main competitors of AnaptysBio include Albireo Pharma (ALBO), Avidity Biosciences (RNA), TG Therapeutics (TGTX), Indivior (INDV), Janux Therapeutics (JANX), ACADIA Pharmaceuticals (ACAD), Arvinas (ARVN), Bausch Health Companies (BHC), Maravai LifeSciences (MRVI), and Deciphera Pharmaceuticals (DCPH). These companies are all part of the "pharmaceutical preparations" industry.
Albireo Pharma (NASDAQ:ALBO) and AnaptysBio (NASDAQ:ANAB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, community ranking, profitability, earnings, risk, media sentiment, institutional ownership and valuation.
In the previous week, AnaptysBio had 5 more articles in the media than Albireo Pharma. MarketBeat recorded 5 mentions for AnaptysBio and 0 mentions for Albireo Pharma. Albireo Pharma's average media sentiment score of 1.09 beat AnaptysBio's score of 0.20 indicating that AnaptysBio is being referred to more favorably in the news media.
Albireo Pharma has a net margin of -228.51% compared to Albireo Pharma's net margin of -711.17%. AnaptysBio's return on equity of -97.13% beat Albireo Pharma's return on equity.
Albireo Pharma has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, AnaptysBio has a beta of -0.32, indicating that its share price is 132% less volatile than the S&P 500.
AnaptysBio has a consensus price target of $46.38, indicating a potential upside of 93.71%. Given Albireo Pharma's higher probable upside, analysts plainly believe AnaptysBio is more favorable than Albireo Pharma.
AnaptysBio received 53 more outperform votes than Albireo Pharma when rated by MarketBeat users. Likewise, 65.61% of users gave AnaptysBio an outperform vote while only 56.65% of users gave Albireo Pharma an outperform vote.
94.3% of Albireo Pharma shares are held by institutional investors. 6.9% of Albireo Pharma shares are held by insiders. Comparatively, 33.7% of AnaptysBio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Albireo Pharma has higher revenue and earnings than AnaptysBio. Albireo Pharma is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.
Summary
AnaptysBio beats Albireo Pharma on 11 of the 17 factors compared between the two stocks.
Get AnaptysBio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
AnaptysBio Competitors List
Related Companies and Tools